UiPath Inc
NYSE:PATH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
UiPath Inc
NYSE:PATH
|
US |
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
US |
|
E
|
Eight Capital Partners PLC
F:ECS
|
UK |
|
Corcept Therapeutics Inc
NASDAQ:CORT
|
US |
|
Pembina Pipeline Corp
TSX:PPL
|
CA |
|
Melco Resorts & Entertainment Ltd
NASDAQ:MLCO
|
HK |
|
Monroe Capital Corp
NASDAQ:MRCC
|
US |
Wall St Price Targets
PATH Price Targets Summary
UiPath Inc
According to Wall Street analysts, the average 1-year price target for PATH is 14.06 USD with a low forecast of 12.12 USD and a high forecast of 17.85 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PATH's stock price target?
Price Target
14.06
USD
According to Wall Street analysts, the average 1-year price target for PATH is 14.06 USD with a low forecast of 12.12 USD and a high forecast of 17.85 USD.
What is the Revenue forecast for UiPath Inc?
Projected CAGR
9%
Over the last 6 years, the compound annual growth rate for Revenue has been 30%. The projected CAGR for the next 3 years is 9%.
What is the Operating Income forecast for UiPath Inc?
Projected CAGR
107%
The compound annual growth rate for Operating Income over the next 3 years is 107%.
What is the Net Income forecast for UiPath Inc?
Projected CAGR
24%
The compound annual growth rate for Net Income over the next 3 years is 24%.
